Cochrane · systematic review · CD008327
Interventions for bone disease in children with chronic kidney disease
Geary Denis F, Hodson Elisabeth M, Craig Jonathan C · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
37
current version
GRADE rated
37
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 21 · 56.8%Low 11 · 29.7%Moderate 5 · 13.5%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Intraperitoneal versus oral calcitriol for bone disease in children with chronic kidney disease
Population: patients with bone disease in children with chronic kidney disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Abnormal bone histology Bone biopsy Intraperitoneal vs oral calcitriol | RR 1.06 [0.7, 1.61] | 1 study · 33 participants | Low Downgraded: imprecision |
Adynamic bone disease Bone histology Intraperitoneal vs oral calcitriol | RR 1.49 [0.59, 3.74] | 1 study · 33 participants | Low Downgraded: imprecision |
Osteitis fibrosa Bone histology Intraperitoneal vs oral calcitriol | RR 0.35 [0.08, 1.51] | 1 study · 33 participants | Low Downgraded: imprecision |
PTH pg/mL Intraperitoneal vs oral calcitriol | no estimate extracted | 1 study · 33 participants | Low Downgraded: imprecision |
Adverse events ‐ Calcium > 11 mg/dL Intraperitoneal vs oral calcitriol | no estimate extracted | 1 study · 33 participants | Low Downgraded: imprecision |
Adverse events ‐ Phosphate > 7.0 mg/dL Intraperitoneal vs oral calcitriol | no estimate extracted | 1 study · 33 participants | Low Downgraded: imprecision |
Peritonitis episodes/patient‐months Intraperitoneal vs oral calcitriol | no estimate extracted | 1 study · 21 participants | Low Downgraded: imprecision |
Intermittent oral versus daily oral calcitriol for bone disease in children with chronic kidney disease
Population: patients with bone disease in children with chronic kidney disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in height SDS Intermittent oral vs daily oral calcitriol | no estimate extracted | 1 study · 24 participants | Very low Downgraded: risk of bias, imprecision |
Fall in PTH % Intermittent oral vs daily oral calcitriol | no estimate extracted | 2 studies · 83 participants | Moderate Downgraded: imprecision |
Fall in PTH Intermittent oral vs daily oral calcitriol | RR 0.88 [0.65, 1.19] | 1 study · 59 participants | Moderate Downgraded: imprecision |
Kidney function mL/min/1.73 m(2) Intermittent oral vs daily oral calcitriol | no estimate extracted | 2 studies · 83 participants | Moderate Downgraded: imprecision |
Adverse events ‐ Calcium > 11.5 mg/dL Intermittent oral vs daily oral calcitriol | no estimate extracted | 2 studies · 80 participants | Moderate Downgraded: imprecision |
Adverse events ‐ Phosphorus level > 7.5 mg/dL Intermittent oral vs daily oral calcitriol | no estimate extracted | 1 study · 59 participants | Low Downgraded: imprecision |
Vitamin D preparations versus placebo/no treatment for bone disease in children with chronic kidney disease
Population: patients with bone disease in children with chronic kidney disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PTH pg/mL Vitamin D preparations vs placebo/no treatment | no estimate extracted | 1 study · 12 participants | Low |
Number without 30% fall in PTH on two occasions Vitamin D preparations vs placebo/no treatment | RR 0.6 [0.4, 0.89] | 2 studies · 76 participants | Low |
Hypercalcaemia Vitamin D preparations vs placebo/no treatment | no estimate extracted | 4 studies · 103 participants | Low Downgraded: imprecision, inconsistency |
Change in calcium‐phosphorus product mg(2)/dL(2) Vitamin D preparations vs placebo/no treatment | no estimate extracted | 2 studies · 76 participants | Moderate |
Calcitriol versus ergocalciferol for bone disease in children with chronic kidney disease
Population: patients with bone disease in children with chronic kidney disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Height velocity equal to or greater than expected Calcitriol vs ergocalciferol | RR 0.22 [0.03, 1.53] | 1 study · 15 participants | Very low Downgraded: risk of bias |
Improved bone histology Calcitriol vs ergocalciferol | RR 1.53 [0.77, 3.06] | 1 study · 15 participants | Very low Downgraded: risk of bias |
PTH ng/mL Calcitriol vs ergocalciferol | no estimate extracted | 1 study · 13 participants | Very low Downgraded: risk of bias |
Hypercalcaemia Calcitriol vs ergocalciferol | RR 1.75 [0.68, 4.5] | 1 study · 15 participants | Very low Downgraded: risk of bias |
Calcium mmol/L Calcitriol vs ergocalciferol | no estimate extracted | 1 study · 13 participants | Very low Downgraded: risk of bias |
Phosphorus mmol/L Calcitriol vs ergocalciferol | no estimate extracted | 1 study · 13 participants | Very low Downgraded: risk of bias |
ALP U/L Calcitriol vs ergocalciferol | no estimate extracted | 1 study · 13 participants | Very low Downgraded: risk of bias |
Calcium carbonate versus aluminium hydroxide for bone disease in children with chronic kidney disease
Population: patients with bone disease in children with chronic kidney disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Height SDS Calcium carbonate vs aluminium hydroxide | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
Abnormal bone biopsy Bone histology Calcium carbonate vs aluminium hydroxide | RR 0.35 [0.13, 0.95] | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
Bone aluminium mg/kg dry weight Calcium carbonate vs aluminium hydroxide | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
PTH mL‐Eq/L Calcium carbonate vs aluminium hydroxide | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
ALP U/L Calcium carbonate vs aluminium hydroxide | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
Hypercalcaemia Calcium carbonate vs aluminium hydroxide | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
Sevelamer versus calcium carbonate for bone disease in children with chronic kidney disease
Population: patients with bone disease in children with chronic kidney disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Bone formation rate um(2)/mm(2)/d Sevelamer vs calcium carbonate | no estimate extracted | 1 study · 29 participants | Very low Downgraded: risk of bias |
Fall in bone formation rate % Sevelamer vs calcium carbonate | no estimate extracted | 1 study · 29 participants | Very low Downgraded: risk of bias |
PTH pg/mL Sevelamer vs calcium carbonate | no estimate extracted | 1 study · 29 participants | Very low Downgraded: risk of bias |
ALP U/L Sevelamer vs calcium carbonate | no estimate extracted | 1 study · 29 participants | Very low Downgraded: risk of bias |
Calcium‐phosphorous product mg(2)/dL(2) Sevelamer vs calcium carbonate | no estimate extracted | 1 study · 29 participants | Very low Downgraded: risk of bias |
Calcium mg/dL Sevelamer vs calcium carbonate | no estimate extracted | 1 study · 29 participants | Very low Downgraded: risk of bias |
Phosphorus mg/dL Sevelamer vs calcium carbonate | no estimate extracted | 1 study · 29 participants | Very low Downgraded: risk of bias |